Dermatology

A practical, evidence-based overview of how to recognize hidradenitis suppurativa early, stage disease severity, and coordinate care before progression.

Dupilumab shows superior 2-year drug survival rates in atopic dermatitis compared to other biologics and JAK inhibitors, highlighting its effectiveness in treatment persistence.

Two global phase 3 trials found rocatinlimab significantly improved EASI-75 and vIGA-AD outcomes at 24 weeks in people with moderate-to-severe AD with acceptable safety.

Genetic predisposition to psoriasis appears to raise depression risk, offering insights into shared inflammatory mechanisms and implications for screening.

A new meta-analysis reveals monoclonal antibodies, including dupilumab, outperform placebo in treating moderate-to-severe atopic dermatitis.

A multinational survey of HS specialists in Europe found that 81% prescribe antibiotics despite expecting poor response and 79% favor earlier biologic initiation.

Topical roflumilast 0.3% improved IGA, PASI, itch, and symptom scores in plaque psoriasis with a safety profile comparable to vehicle.

KT-621 achieved deep STAT6 degradation and strong 4-week EASI and itch reductions, offering a potential new oral option for moderate–severe AD and other Th2 inflammation-driven disease.

Psychiatric comorbidities affect 25% of AD patients. Here, a check list on when to screen, when to refer, and how to prevent accumulated psychological burden in primary care.

A regular focus on mental heatlh during follow-ups with patients who have atopic dermatitis can be integrated simply with a few thoughtful questions.

Primary care is the ideal setting for management of atopic dermatitis, but certain scenarios, both physical and psychological, call for expert referral.

Controlling atopic dermatitis signs and symptoms early can alter social, emotional, and functional outcomes, sometimes dramatically.

Emotional red flags in AD, eg, sleep loss, isolation, hopelessness, often go unseen. Quick screening questions can surface the real burden individuals carry.

Growing up with AD carries lifelong emotional consequences. Clinicians who recognize these developmental risks can better support patients at every stage.

Up to 1 in 4 patients with atopic dermatitis face anxiety or depression. Primary care clinicians are key to identifying risk and supporting mental well-being.

FDA reviews roflumilast cream for young children with plaque psoriasis, potentially offering a first-of-its-kind topical treatment option.

LEO Pharma reveals promising 32-week results for tralokinumab, showing significant benefits for adults with moderate-to-severe hand eczema.

ACAAI 2025. Phase 3 data show tapinarof cream provides early, sustained improvement and good tolerability in children aged ≥2 years with atopic dermatitis.

Phase 2b findings show rezpegaldesleukin reduced ACQ-5 scores and improved key AD endpoints in participants with comorbid asthma.

Your daily dose of the clinical news you may have missed.

Novel AD therapies targeting OX40, IL-13, IL-36, IL-22, and IL-2 pathways show promise for disease modification and extended dosing intervals in phase 2-3 trials.

Psoriasis, lichen planus, and pityriasis rosea share overlapping presentations and comorbidities, but distinct pathophysiologies require accurate diagnosis and tailored therapeutic approaches.

The approval of roflumilast 0.05% provides a steroid-free, once-daily treatment option for safe and effective long-term management of pediatric eczema.

Remibrutinib is the first oral BTK inhibitor for chronic spontaneous urticaria, with a dual mechanism of action that blocks 2 key autoimmune mechanisms.

The FDA has approved guselkumab for children aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis, making it the first IL-23 inhibitor authorized for pediatric use.